Sernova Biotherapeutics and Seraxis Holdings announced on September 8, 2026 that they’ve signed a definitive agreement to merge into a single company, BetaNova Biotherapeutics, combining two different pieces of the same puzzle: an implantable device that houses insulin-producing cells, and the stem-cell-derived islet cells meant to go inside it. The combined company will be headquartered in Germantown, Maryland, with existing shareholders of each company expected to hold roughly half of BetaNova once the deal closes.
Two Technologies, One Problem
Sernova’s contribution is its Cell Pouch, an implantable device that’s been in human testing for years at the University of Chicago. Sernova has reported that most patients in the trial’s first cohort achieved insulin independence, in some cases sustained for over three years, with islet cells shown to survive and function inside the device for as long as five years. Seraxis brings the other half of the equation: lab-grown pancreatic islet cells manufactured at commercial scale, designed to eventually work without the lifelong immune-suppressing drugs that current islet transplants require. Putting the two together is the basic logic behind the merger — a durable housing device paired with a scalable, lab-made cell source.
“This merger is deeply personal to me – I’ve lived with and suffered from type 1 diabetes most of my life and it drives my passion to overcome it. People with T1D struggle to manage the life-altering loss of insulin production, often resulting in serious co-morbidities. Combining Sernova’s Cell Pouch Bio-hybrid Organ with Seraxis’ stem cell-derived pancreatic islet cells lets us approach the problem differently, bringing us closer to a functional cure. This is very exciting to me and our entire team”, said Jonathan Rigby, President and CEO of Sernova and proposed CEO of BetaNova.
Adding to that, Will Rust, PhD, President and CEO of Seraxis and proposed President and Chief Scientific Officer of BetaNova mentioned “The central challenge in islet cell replacement isn’t just differentiating insulin-producing cells. Those cells must be manufactured with a clinically compliant process at scale, successfully engraft and function, and ultimately be protected from immune-mediated destruction. By combining Seraxis’ islet cells and manufacturing capabilities and immune evasion strategy with Sernova’s Cell Pouch Bio-hybrid Organ, BetaNova brings together critical components of a potential cell-replacement solution within a single strategy.”
What’s Next in the Pipeline
BetaNova’s lead program, SR-02, is an allogeneic (donor-cell-based) islet therapy expected to begin dosing patients in a Phase 1/2 trial in early 2027, with data expected by mid-year. A second, more advanced candidate, SR-03, adds gene edits designed to help the cells evade immune attack altogether, with an IND filing targeted for the second half of 2027. To fund that work, the companies have already lined up a $10 million financing round from existing investors, with the window still open for additional investors through the end of September. BetaNova also intends to pursue a Nasdaq listing in early 2027, pending standard listing requirements.
Deal Mechanics
The merger still needs sign-off from Sernova shareholders, along with court and regulatory approval, and is expected to close in November 2026. Noble Capital Markets advised on the transaction. If the deal falls apart in favor of a competing offer, a $5 million break fee applies. Company insiders holding about 11% of Sernova’s outstanding shares have already agreed to vote in favor of the deal.
About Sernova and Seraxis
Sernova is a clinical-stage regenerative medicine company that’s spent years developing the Cell Pouch, an implantable device designed to give transplanted cells a stable, long-term home in the body by forming a natural, vascularized tissue environment around them. The company’s lead application has been type 1 diabetes, where the Cell Pouch has been tested in an ongoing Phase 1/2 trial at the University of Chicago under principal investigator Dr. Piotr Witkowski — a study that has reported islet cell survival lasting from one to more than five years, along with sustained insulin independence in most first-cohort patients. Beyond diabetes, Sernova has also explored the same underlying device for other chronic conditions where the body is missing a specific biological factor, including thyroid disease and hemophilia A.
Seraxis, based in Germantown, Maryland, focuses on the other side of the equation: manufacturing pancreatic islet cells at commercial scale under current Good Manufacturing Practice (cGMP) standards. The company’s approach starts with donor islet cells that are reprogrammed into a stable, stem-cell-like state so they can be produced and stored at scale, then re-differentiated into functional islet cells at the time of treatment. Seraxis’ central goal is to eventually deliver that cell therapy without requiring patients to stay on lifelong immunosuppressive drugs — first through an immune-tolerizing approach paired with its lead candidate, SR-02, and later through direct gene editing in its follow-on candidate, SR-03, designed to help the cells evade immune detection altogether.
